Cash Interest Paid - Neurogene Inc (NASDAQ:NGNE)

Watchlist Manager

Watchlist

Price: 17.96 USD 2.51%

Market Cap: 278.2m USD

Neurogene Inc
Cash Interest Paid

Quarterly

Annual

TTM

Adjust for Inflation

Cash Flow Statement

Neurogene Inc
Cash Interest Paid Peer Comparison

	Cash Interest Paid	CAGR 3Y	CAGR 5Y	CAGR 10Y
Neurogene Inc NASDAQ:NGNE	Cash Interest Paid $6k	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A
Abbvie Inc NYSE:ABBV	Cash Interest Paid N/A	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A
Gilead Sciences Inc NASDAQ:GILD	Cash Interest Paid N/A	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A
Amgen Inc NASDAQ:AMGN	Cash Interest Paid N/A	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A
Vertex Pharmaceuticals Inc NASDAQ:VRTX	Cash Interest Paid $12.1m	CAGR 3-Years -40%	CAGR 5-Years -26%	CAGR 10-Years -21%
Regeneron Pharmaceuticals Inc NASDAQ:REGN	Cash Interest Paid N/A	CAGR 3-Years N/A	CAGR 5-Years N/A	CAGR 10-Years N/A

Neurogene Inc
Glance View

Market Cap

278.2m USD

Industry

Biotechnology

Neurogene Inc is a US-based company operating in Biotechnology industry. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2014-03-07. Neurogene Inc., formerly Neoleukin Therapeutics, Inc., is focused on developing genetic medicines for patients and their families affected by rare, devastating neurological diseases. The firm is developing novel approaches and treatments to address the limitations of conventional gene therapy in central nervous system disorders. The Company’s novel and proprietary EXACT transgene regulation platform technology allows for the delivery of therapeutic levels while limiting transgene toxicity associated with conventional gene therapy. The firm's product candidate, NGN-401, is an investigational adeno-associated virus (AAV9) gene therapy candidate for Rett syndrome purposefully designed and administered to maximize therapeutic activity while averting transgene overexpression toxicities. The firm is also developing NGN-101 for the treatment of CLN5 Batten disease. The company is advancing multiple discovery-stage candidates leveraging its EXACT transgene regulation technology.

View NGNE Analysis

NGNE Intrinsic Value

Overvaluation 51%

Intrinsic Value

Price

What is Intrinsic Value?

Economic Moat is a concept popularized by Warren Buffett to describe a company's durable competitive advantage. It represents the 'moat' that protects a company from competitors and helps it sustain profitability over the long term. Our analysis of the past 10 years showed that companies with a wide economic moat significantly outperformed the market, delivering +645% returns compared to +189% for the S&P 500.

Our research into Economic Moat performance spans the past 10 years and focuses on companies with a wide economic moat. For this analysis, we calculated the average stock price returns of these companies, comparing them to the performance of the S&P 500 index over the same period.

The results were compelling: wide moat stocks achieved a remarkable +645% average return, compared to +188% for the broader market. This difference highlights the long-term benefits of investing in businesses that can maintain their market position and pricing power over time.

Note: This research does not account for survivorship bias. Past performance is not indicative of future results.

Determining whether a company has an economic moat requires both a deep dive into financial metrics and a qualitative assessment of its competitive position. Our analysts conduct a rigorous evaluation that focuses on identifying structural advantages that enable a company to sustain profitability and defend its market share over the long term.

The process begins with an analysis of a company’s historical financial performance. We assess how consistently the company has generated returns above its cost of capital and whether those returns have been stable or improving. However, financial performance alone doesn’t reveal the full picture. To understand the sources of these advantages, we evaluate five key drivers of economic moats:

Network Effect: We analyze whether the value of a company’s product or service grows as its user base expands. Platforms like payment systems or marketplaces benefit from this self-reinforcing.

Switching Costs: We assess whether customers face significant costs or disruptions when switching to a competitor’s product or service. High switching costs create customer stickiness and provide pricing power.

Intangible Assets: Strong brands, patents, and regulatory licenses can protect a company’s market position by creating barriers for competitors or enabling premium pricing. For example, a well-recognized consumer brand may command higher customer loyalty and margins.

Efficient scale: Occurs when a market is optimally served by one or a few players, making it unprofitable for new entrants to compete. This typically happens in industries with high fixed costs or geographic constraints, such as utilities or pipelines.

Cost Advantage: Companies with structural cost advantages can produce goods or services at a lower cost than their competitors, enabling them to offer competitive pricing or maintain higher margins. These advantages often arise from economies of scale, superior supply chain management, or proprietary technology. Firms like Walmart leverage their massive scale to negotiate better terms with suppliers, allowing them to undercut competitors on price.

By examining these factors in combination with a company’s financial performance and market positioning, we classify each company into one of three categories:

This rigorous evaluation ensures that our moat ratings are both comprehensive and reliable, giving investors the tools they need to make well-informed, long-term decisions.

The AI Assistant may sometimes provide inaccurate information.

Make your own investment decisions or consult a licensed financial advisor.

Neurogene Inc
NASDAQ:NGNE

Neurogene Inc
Cash Interest Paid

Neurogene Inc
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Neurogene Inc
Glance View

See Also

What is Neurogene Inc's Cash Interest Paid?

Cash Interest Paid
6k USD

What is Neurogene Inc's Cash Interest Paid growth rate?

Cash Interest Paid CAGR 1Y
-40%

Company

Help

Tools

Stocks

52 Week Range	7.34 34.37
Price Target

Neurogene Inc NASDAQ:NGNE

Neurogene Inc Cash Interest Paid

Neurogene Inc Cash Interest Paid Peer Comparison

Competitors Analysis Latest Figures & CAGR of Competitors

Neurogene Inc Glance View

See Also

What is Neurogene Inc's Cash Interest Paid? Cash Interest Paid 6k USD

What is Neurogene Inc's Cash Interest Paid growth rate? Cash Interest Paid CAGR 1Y -40%

Company

Help

Tools

Stocks

Neurogene Inc
NASDAQ:NGNE

Neurogene Inc
Cash Interest Paid

Neurogene Inc
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Neurogene Inc
Glance View

What is Neurogene Inc's Cash Interest Paid?

Cash Interest Paid
6k USD

What is Neurogene Inc's Cash Interest Paid growth rate?

Cash Interest Paid CAGR 1Y
-40%